83 Clemenceau Avenue #12-03 UE Square
June 28, 2019
U.S. Securities and Exchange Commission
Office of Healthcare and Insurance
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Ms. Ada D. Sarmento
ASLAN Pharmaceuticals Limited
Registration Statement on Form F-1 (File No. 333-231847)
Request for Withdrawal
Ladies and Gentlemen:
ASLAN Pharmaceuticals Limited (the Company) hereby applies for withdrawal of the Companys Registration Statement (File No. 333-231847) on Form F-1 confidentially submitted to the Securities and Exchange Commission (the Commission) on May 17, 2019 and filed with the Commission on May 31, 2019 and amended on June 17, 2019 (the Registration Statement), together with all exhibits thereto. Pursuant to Rule 477 of the Securities Act of 1933, as amended (the Act), the Company is withdrawing the Registration Statement, which has not been declared effective, because the Company does not intend to pursue the contemplated public offering at this time. Since the Registration Statement was not declared effective by the Commission, no shares were sold in connection with the offering described in the Registration Statement.
The Company also requests in accordance with Rule 457(p) of the Act that all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use.
If you have any questions regarding the foregoing application for withdrawal, please contact Robert Phillips of Cooley LLP at (415) 693-2020, or in his absence, Carlos Ramirez at (858) 550-6157.
|ASLAN Pharmaceuticals Limited|
|By:||/s/ Carl Firth|
|Carl Firth, Ph.D.|
|Chief Executive Officer and Chairman|
|cc:||Kiran Asarpota, ASLAN Pharmaceuticals Limited|
|Robert W. Phillips, Cooley LLP|
|Kristin VanderPas, Cooley LLP|
|Carlos Ramirez, Cooley LLP|
|Alan F. Denenberg, Davis Polk & Wardwell LLP|